NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

XRTX

XORTX Therapeutics Inc

Jul 11 • 04:00PM ET

0.9575

Dollar change +0.0875
Percentage change 10.06	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA ONC FATE IOVA ATRA EDIT BLUE KPTI SGMO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	4.08%	Shs Outstand	3.79M	Perf Week	6.38%
Market Cap	3.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.63M	Perf Month	7.26%
Enterprise Value	1.75M	PEG	-	EPS next Q	-	Inst Own	4.71%	Short Float	0.08%	Perf Quarter	11.21%
Income	-0.99M	P/S	-	EPS this Y	-	Inst Trans	-51.85%	Short Ratio	0.03	Perf Half Y	-19.54%
Sales	0.00M	P/B	1.32	EPS next Y	-	ROA	-20.80%	Short Interest	0.00M	Perf YTD	-15.24%
Book/sh	0.72	P/C	1.91	EPS next 5Y	-	ROE	-37.96%	52W High	2.98 -67.87%	Perf Year	-44.29%
Cash/sh	0.50	P/FCF	-	EPS past 3/5Y	1.50% -7.63%	ROIC	-36.23%	52W Low	0.80 19.39%	Perf 3Y	-92.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.85% 7.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	79.33%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.78	EPS Q/Q	84.95%	SMA20	8.19%	Beta	0.71	Target Price	14.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	1.95%	Rel Volume	0.48	Prev Close	0.87
Employees	-	LT Debt/Eq	0.00	Earnings	May 19 AMC	SMA200	-14.22%	Avg Volume	106.31K	Price	0.96
IPO	Nov 28, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	51,096	Change	10.06%

Jun-26-25 07:00AM	XORTX Announces USD $925,000 Private Placement (GlobeNewswire)
May-19-25 07:00AM	XORTX Announces USD $3 Million Offering (GlobeNewswire) -14.02%
Apr-30-25 07:00AM	XORTX Provides Update on FDA Type B Meeting Request (GlobeNewswire)
Apr-28-25 07:00AM	XORTX Announces Grant of European Patent (GlobeNewswire)
Apr-17-25 07:45PM	XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +9.98% -8.23%
07:00AM	Loading…
Mar-19-25 07:00AM	XORTX Announces Update for Discussion with the FDA (GlobeNewswire) +6.32%
Feb-24-25 07:00AM	XORTX Commences Gout Program NDA Discussions with the FDA (GlobeNewswire)
Jan-29-25 07:00AM	XORTX to Present at Microcap Conference (GlobeNewswire)
Jan-17-25 05:00PM	XORTX Announces Change of Auditor (GlobeNewswire) -5.84%
Jan-06-25 07:00AM	XORTX Adds Late Stage Gout Program to Pipeline (GlobeNewswire) +9.17%
Dec-19-24 07:00AM	XORTX Strengthens Executive Team (GlobeNewswire)
Dec-12-24 09:17AM	XORTX Announces Presentation at the Rare and Genetic Disease Summit (GlobeNewswire)
Oct-24-24 07:00AM	XORTX Sponsored Study Presented at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire) -5.06%
Oct-18-24 04:00PM	XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -9.04%
Oct-17-24 08:00AM	XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -16.13%
05:00AM	Loading…
Oct-09-24 05:00AM	XORTX Initiates Precision Medicine Program (GlobeNewswire) -5.56%
Sep-13-24 07:00AM	XORTX Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire)
Sep-12-24 05:30PM	XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A (GlobeNewswire)
Sep-06-24 05:30PM	XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders (GlobeNewswire) -18.03%
Sep-03-24 12:30PM	Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders (GlobeNewswire) +5.24%
Aug-29-24 07:00AM	XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism (GlobeNewswire) +134.78%
Aug-23-24 07:00AM	XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders (GlobeNewswire) +5.62%
Aug-20-24 07:00AM	XORTX Announces Presentation at American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Jun-04-24 08:30AM	XORTX to Present at BIO International Convention 2024 (GlobeNewswire)
May-20-24 11:53AM	XRTX Stock Earnings: XORTX Therapeutics Reported Results for Q1 2024 (InvestorPlace)
May-17-24 07:00AM	XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO (GlobeNewswire) +6.38%
Apr-30-24 01:54PM	XORTX Reprices Warrants Issued in Connection with Previous Private Placements (GlobeNewswire)
Apr-22-24 07:00AM	XORTX Announces Publication of Key Research in ADPKD (GlobeNewswire)
Apr-08-24 07:30AM	XORTX Welcomes New Member to the Board of Directors (GlobeNewswire) +5.53%
07:00AM	XORTX Announces Participation in Spring 2024 Investor Conferences (GlobeNewswire)
05:00AM	Loading…
Mar-27-24 05:00AM	XORTX Announces New Clinical Advisory Board Member (GlobeNewswire) -5.26%
Mar-19-24 09:30AM	XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial (News Direct)
05:00AM	XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial (GlobeNewswire)
Mar-11-24 07:00AM	XORTX Reprices Warrants Issued in Connection with Previous Private Placements (GlobeNewswire) -6.71%
Mar-04-24 07:00AM	XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units (GlobeNewswire) +5.06%
Feb-15-24 07:00AM	XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units (GlobeNewswire)
Feb-01-24 08:46PM	XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units (GlobeNewswire)
Jan-15-24 07:00AM	XORTX Announces $2 Million Public Offering (GlobeNewswire)
Jan-03-24 07:00AM	XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease (GlobeNewswire) +13.18%
Jan-02-24 07:00AM	XORTX Welcomes New Member to the Board of Directors (GlobeNewswire)
Nov-30-23 07:30AM	XORTX Announces US ATM Offering (GlobeNewswire) -19.74%
Nov-29-23 07:00AM	XORTX Meets Nasdaq Continued Listing Requirements (GlobeNewswire)
Nov-10-23 07:00AM	XORTX Clarifies Timing for Share Consolidation (GlobeNewswire)
Nov-08-23 05:00PM	XORTX Announces Share Consolidation (GlobeNewswire) -6.20% -7.68%
Nov-02-23 07:00AM	XORTX Sponsored Study Presented at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-27-23 05:30PM	XORTX Announces Results of Special Meeting of Shareholders (GlobeNewswire) -14.34% +7.48%
Oct-25-23 05:00PM	XORTX Announces Date for Rescheduled Special Meeting of Shareholders (GlobeNewswire) -14.56% -12.90%
07:00AM	XORTX Announces Rescheduling of Special Meeting of Shareholders (GlobeNewswire)
Oct-23-23 09:10AM	Why Is Xortx Therapeutics (XRTX) Stock Down 27% Today? (InvestorPlace) -34.18%
Oct-20-23 08:42AM	Why Is Xortx Therapeutics (XRTX) Stock Up 110% Today? (InvestorPlace) +83.09%
Oct-12-23 07:00AM	XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution (GlobeNewswire) -10.26%
Oct-04-23 07:00AM	XORTX Calls Special Meeting of Shareholders (GlobeNewswire) -23.41%
Sep-28-23 07:00AM	XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Sep-11-23 07:00AM	XORTX Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-07-23 07:00AM	XORTX Joins the Kidney Foundation and Kidney March (GlobeNewswire) -5.22%
Aug-29-23 07:00AM	XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease (GlobeNewswire)
Aug-04-23 05:00PM	XORTX Appoints Chief Financial Officer (GlobeNewswire)
Jun-29-23 08:00AM	XORTX Announces Results of Annual and Special Meeting of Shareholders (GlobeNewswire) -7.72%
Jun-23-23 08:51PM	XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Companys Upcoming Annual and Special Meeting of Shareholders (GlobeNewswire)
Jun-06-23 07:00AM	XORTX Announces PKD Presentation (GlobeNewswire)
May-24-23 07:00AM	XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) +8.11%
May-04-23 07:00AM	FDA Confirms Eligibility of XORLO for Accelerated Approval (GlobeNewswire)
Apr-21-23 07:00AM	XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease (GlobeNewswire)
Mar-14-23 07:00AM	XORTX Announces Type D Meeting with FDA to be held May 1, 2023 (GlobeNewswire)
Feb-07-23 07:00AM	XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones (GlobeNewswire)
Feb-01-23 07:00AM	XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease (GlobeNewswire) +8.47%
Jan-19-23 07:00AM	XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial (GlobeNewswire) +11.14%
Jan-03-23 07:00AM	XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression (GlobeNewswire)
Dec-19-22 07:00AM	XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study (GlobeNewswire) -6.68%
Dec-08-22 07:00AM	XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
Nov-28-22 07:00AM	XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study (GlobeNewswire)
Nov-25-22 05:45PM	XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +14.62%
Nov-16-22 07:00AM	XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer (GlobeNewswire) -8.96%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
Nov-03-22 05:00PM	XORTX Presents New Proof of Concept Data at American Society of Nephrology (GlobeNewswire)
10:15AM	XORTX Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 07:00AM	XORTX Receives Further No Objection Letter from Health Canada (GlobeNewswire)
Oct-25-22 07:00AM	XORTX Sponsored American Society of Nephrology Study Abstract Available Online (GlobeNewswire)
Oct-07-22 06:02PM	XORTX Announces Closing of US$5 Million Public Offering (GlobeNewswire)
Oct-04-22 08:30AM	XORTX Announces US$5 Million Public Offering (GlobeNewswire) -14.28%
Sep-19-22 07:00AM	XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration (GlobeNewswire) -7.03%
Sep-01-22 07:00AM	XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology Kidney Week 2022 (GlobeNewswire)
Aug-22-22 07:00AM	XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study (GlobeNewswire) +9.27%
Aug-04-22 07:00AM	XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration (GlobeNewswire) +5.58%
Jul-22-22 08:00AM	XORTX Reports Annual & Special Meeting Results (GlobeNewswire)
Jul-19-22 07:00AM	XORTX Announces Submission to European Medicines Agency (GlobeNewswire) -8.70%
Jul-13-22 07:00AM	XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial (GlobeNewswire) +48.36%
Jul-07-22 07:00AM	XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA) (GlobeNewswire) +7.82%
Jun-21-22 07:00AM	XORTX Announces Fireside Chat with XORTX CEO (GlobeNewswire)
Jun-13-22 08:55AM	XORTX to Present at BIO International Convention 2022 (GlobeNewswire) -12.34%
Jun-08-22 07:00AM	XORTX to Present at LD Micro Invitational 2022 (GlobeNewswire)
Jun-06-22 07:00AM	XORTX Welcomes New Member to the Board of Directors and Appoints Chair (GlobeNewswire) +11.72%
May-25-22 08:00AM	XORTX to Present at H. C. Wainwright Global Investment Conference 2022 (GlobeNewswire) -7.06%
May-05-22 07:00AM	XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire) +8.75%
May-03-22 07:00AM	XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial (GlobeNewswire) +57.76%
Apr-20-22 07:00AM	XORTX Receives Small and Medium Enterprise Status for the European Union (GlobeNewswire)
Apr-12-22 07:00AM	XORTX Receives No Objection Letter from Health Canada (GlobeNewswire)
Apr-07-22 07:00AM	XORTX Announces Grant of US Patent (GlobeNewswire)
Mar-31-22 07:00AM	XORTX Files IND with US FDA (GlobeNewswire)
Mar-23-22 07:00AM	XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection (GlobeNewswire) +43.80%

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XRTX

XORTX Therapeutics Inc

Upgrade your FINVIZ experience